Skip to main content

Probiotics for the Treatment of Inflammatory Bowel Disease

Current Gastroenterology Reports volume 14, pages 324–333 (2012)Cite this article

Abstract

Probiotics are organisms which provide a desired and beneficial effect on human health. With recent evidence implicating a disruption in the balance of the gastrointestinal microbiome and intestinal immunity as a potential trigger for inflammatory bowel disease (IBD), there has been growing interest in using probiotics as an adjunct to standard anti-inflammatory and immune suppressing therapy. Animal models describe potential and plausible mechanisms of action for probiotics to counter inflammation of colonic mucosa. Although there are insufficient data to recommend probiotics in ulcerative colitis or Crohn’s disease, good evidence supports the use of specific probiotics for maintenance of remission in pouchitis. Although there are limited regulatory standards for the agents, probiotics are relatively safe with minimal reported side effects or contraindications. More rigorous studies need to be published supporting efficacy and safety of these agents before they become a mainstay of IBD medical treatment.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–29.

    PubMed  Article  CAS  Google Scholar 

  2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–34.

    PubMed  Article  CAS  Google Scholar 

  3. Quigley EM: Prebiotics and probiotics: Their role in the management of gastrointestinal disorders in adults. Nutr Clin Pract

  4. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5:e177.

    PubMed  Article  Google Scholar 

  5. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;361:512–9.

    PubMed  Article  Google Scholar 

  6. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol. 2002;16:915–31.

    PubMed  Article  Google Scholar 

  7. Bhan AK, Mizoguchi E, Smith RN, Mizoguchi A. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev. 1999;169:195–207.

    PubMed  Article  CAS  Google Scholar 

  8. Bamias G, Nyce MR, De La Rue SA, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med. 2005;143:895–904.

    PubMed  CAS  Google Scholar 

  9. Onderdonk AB, Franklin ML, Cisneros RL. Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora. Infect Immun. 1981;32:225–31.

    PubMed  CAS  Google Scholar 

  10. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224–31.

    PubMed  CAS  Google Scholar 

  11. Harper PH, Lee EC, Kettlewell MG, Bennett MK, Jewell DP. Role of the faecal stream in the maintenance of crohn's colitis. Gut. 1985;26:279–84.

    PubMed  Article  CAS  Google Scholar 

  12. D'Haens GR, Geboes K, Peeters M, et al. P: Early lesions of recurrent crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262–7.

    PubMed  Article  Google Scholar 

  13. de Silva HJ, Millard PR, Soper N, et al. Effects of the faecal stream and stasis on the ileal pouch mucosa. Gut. 1991;32:1166–9.

    PubMed  Article  Google Scholar 

  14. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in nod2 associated with susceptibility to crohn's disease. Nature. 2001;411:603–6.

    PubMed  Article  CAS  Google Scholar 

  15. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44–54.

    PubMed  Article  Google Scholar 

  16. Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with crohn's disease of the colon. Gut. 2003;52:237–42.

    PubMed  Article  CAS  Google Scholar 

  17. Ruseler-van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut. 1994;35:658–64.

    PubMed  Article  CAS  Google Scholar 

  18. Sartor RB. Mechanisms of disease: Pathogenesis of crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390–407.

    PubMed  Article  CAS  Google Scholar 

  19. Clavel T, Haller D. Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: Implications for chronic inflammation. Inflamm Bowel Dis. 2007;13:1153–64.

    PubMed  Article  Google Scholar 

  20. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: What are the risks? Am J Clin Nutr. 2006;83:1256–64. quiz 1446–1257.

    PubMed  CAS  Google Scholar 

  21. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1585–96.

    PubMed  Article  Google Scholar 

  22. Yoon SS, Sun J: Probiotics, nuclear receptor signaling, and anti-inflammatory pathways. Gastroenterol Res Pract; 2011:971938

  23. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev. 2004;28:405–40.

    PubMed  Article  CAS  Google Scholar 

  24. Collado MC, Surono IS, Meriluoto J, Salminen S. Potential probiotic characteristics of lactobacillus and enterococcus strains isolated from traditional dadih fermented milk against pathogen intestinal colonization. J Food Prot. 2007;70:700–5.

    PubMed  Google Scholar 

  25. Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol. 2007;45:454–60.

    PubMed  Article  CAS  Google Scholar 

  26. Candela M, Seibold G, Vitali B, et al. Real-time pcr quantification of bacterial adhesion to caco-2 cells: Competition between bifidobacteria and enteropathogens. Res Microbiol. 2005;156:887–95.

    PubMed  Article  CAS  Google Scholar 

  27. Michail S, Sylvester F, Fuchs G, Issenman R. Clinical efficacy of probiotics: Review of the evidence with focus on children. J Pediatr Gastroenterol Nutr. 2006;43:550–7.

    PubMed  Article  Google Scholar 

  28. Rioux KP, Madsen KL, Fedorak RN. The role of enteric microflora in inflammatory bowel disease: Human and animal studies with probiotics and prebiotics. Gastroenterol Clin North Am. 2005;34:465–82. ix.

    PubMed  Article  Google Scholar 

  29. Madsen KL. Inflammatory bowel disease: Lessons from the il-10 gene-deficient mouse. Clin Invest Med. 2001;24:250–7.

    PubMed  CAS  Google Scholar 

  30. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular muc3 mucin secretion follows adherence of lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52:827–33.

    PubMed  Article  CAS  Google Scholar 

  31. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: Definition, pathogenesis, and treatment. Gastroenterology. 1994;107:1856–60.

    PubMed  CAS  Google Scholar 

  32. Gosselink MP, Schouten WR, van Lieshout LM, et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain lactobacillus rhamnosus gg. Dis Colon Rectum. 2004;47:876–84.

    PubMed  Article  Google Scholar 

  33. Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol. 2003;38:409–14.

    PubMed  Article  CAS  Google Scholar 

  34. Kuisma J, Mentula S, Jarvinen H, et al. Effect of lactobacillus rhamnosus gg on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17:509–15.

    PubMed  Article  CAS  Google Scholar 

  35. Laake KO, Line PD, Grzyb K, et al. Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a j-configurated ileal-pouch-anal-anastomosis (ipaa). Scand J Gastroenterol. 2004;39:1228–35.

    PubMed  Article  CAS  Google Scholar 

  36. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202–9.

    PubMed  Article  Google Scholar 

  37. Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: Experience in clinical practice. Aliment Pharmacol Ther. 2005;22:721–8.

    PubMed  Article  CAS  Google Scholar 

  38. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (vsl#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108–14.

    PubMed  Article  CAS  Google Scholar 

  39. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305–9.

    PubMed  Article  CAS  Google Scholar 

  40. • McLaughlin SD, Walker AW, Churcher C, et al.: The bacteriology of pouchitis: A molecular phylogenetic analysis using 16s rrna gene cloning and sequencing. Ann Surg;252:90–98. This well done study demonstrates reduced bacterial diversity in the pouches of those with UC versus those with FAP. Pouchitis is associated with a further reduction in biodiversity.

  41. Uronis JM, Arthur JC, Keku T, et al.: Gut microbial diversity is reduced by the probiotic vsl#3 and correlates with decreased tnbs-induced colitis. Inflamm Bowel Dis;17:289–297.

  42. Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis. 2008;14:662–8. This.

    PubMed  Article  Google Scholar 

  43. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–51.

    PubMed  Article  Google Scholar 

  44. Turroni S, Vitali B, Candela M, et al. Antibiotics and probiotics in chronic pouchitis: A comparative proteomic approach. World J Gastroenterol. 2010;16:30–41.

    PubMed  CAS  Google Scholar 

  45. Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004;10:PI126–31.

    PubMed  CAS  Google Scholar 

  46. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J: Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered escherichia coli nissle 1917 (ecn). BMC Complement Altern Med. 10:13.

  47. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet. 1999;354:635–9.

    PubMed  Article  CAS  Google Scholar 

  48. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20:1133–41.

    PubMed  Article  CAS  Google Scholar 

  49. Guslandi M, Giollo P, Testoni PA. A pilot trial of saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:697–8.

    PubMed  Article  Google Scholar 

  50. Bibiloni R, Fedorak RN, Tannock GW, et al. Vsl#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539–46.

    PubMed  Article  Google Scholar 

  51. • Sood A, Midha V, Makharia GK, et al.: The probiotic preparation, vsl#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:1202–1209, 1209 e1201. This recent large double blind, placebo controlled study of VSL #3 is one of the more recent positive studies that may suggest that this will be a useful adjunct to our current medical therapies for induction of remission in mild to moderate ulcerative colitis. As mentioned more studies with more robust outcomes and longer follow up are necessary before these agents can be used routinely.

    PubMed  Article  Google Scholar 

  52. Tursi A, Brandimarte G, Papa A, et al.: Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic vsl#3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol;105:2218–2227.

  53. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (vsl#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437–43.

    PubMed  Article  CAS  Google Scholar 

  54. Mallon P, McKay D, Kirk S, Gardiner K: Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;CD005573.

  55. Zigra PI, Maipa VE, Alamanos YP. Probiotics and remission of ulcerative colitis: A systematic review. Neth J Med. 2007;65:411–8.

    PubMed  CAS  Google Scholar 

  56. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853–8.

    PubMed  Article  CAS  Google Scholar 

  57. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic escherichia coli nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–23.

    PubMed  Article  CAS  Google Scholar 

  58. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of lactobacillus gg in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1567–74.

    PubMed  Article  CAS  Google Scholar 

  59. Huynh HQ, deBruyn J, Guan L, et al. Probiotic preparation vsl#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study. Inflamm Bowel Dis. 2009;15:760–8.

    PubMed  Article  Google Scholar 

  60. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2011;12:CD007443.

    PubMed  Google Scholar 

  61. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is lactobacillus gg helpful in children with crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000;31:453–7.

    PubMed  Article  CAS  Google Scholar 

  62. Fujimori S, Tatsuguchi A, Gudis K, et al. High dose probiotic and prebiotic cotherapy for remission induction of active crohn's disease. J Gastroenterol Hepatol. 2007;22:1199–204.

    PubMed  Article  Google Scholar 

  63. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus gg in inducing and maintaining remission of crohn's disease. BMC Gastroenterol. 2004;4:5.

    PubMed  Article  Google Scholar 

  64. Butterworth AD, Thomas AG, Akobeng AK: Probiotics for induction of remission in crohn's disease. Cochrane Database Syst Rev 2008;CD006634.

  65. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of lactobacillus gg versus placebo in addition to standard maintenance therapy for children with crohn's disease. Inflamm Bowel Dis. 2005;11:833–9.

    PubMed  Article  Google Scholar 

  66. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of crohn's disease. Dig Dis Sci. 2000;45:1462–4.

    PubMed  Article  CAS  Google Scholar 

  67. Malchow HA. Crohn's disease and escherichia coli. A new approach in therapy to maintain remission of colonic crohn's disease? J Clin Gastroenterol. 1997;25:653–8.

    PubMed  Article  CAS  Google Scholar 

  68. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F: Probiotics for maintenance of remission in crohn's disease. Cochrane Database Syst Rev 2006;CD004826.

  69. • Rahimi R, Nikfar S, Rahimi F, et al.: A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in crohn's disease. Dig Dis Sci 2008;53:2524–2531. This is the most recent meta-analysis on the role of probiotics to maintain remission in Crohn’s disease, which had a similar negative results to a Cochrane Review performed a few years prior. A total of 8 randomized controlled studies were included in study. Clinical relapse yielded odds ratio of 0.92 (0.52-1.62) and endoscopic relapse was 0.97 (0.54 = 1.78).

    PubMed  Article  Google Scholar 

  70. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of lactobacillus johnsonii la1 for prophylaxis of postoperative recurrence in crohn's disease: A randomised, double blind, placebo controlled getaid trial. Gut. 2006;55:842–7.

    PubMed  Article  CAS  Google Scholar 

  71. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for crohn's disease: A randomised controlled trial with lactobacillus gg. Gut. 2002;51:405–9.

    PubMed  Article  CAS  Google Scholar 

  72. Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (lactobacillus johnsonii, la1) on early endoscopic recurrence of crohn's disease after lleo-caecal resection. Inflamm Bowel Dis. 2007;13:135–42.

    PubMed  Article  Google Scholar 

  73. Chermesh I, Tamir A, Reshef R, et al. Failure of synbiotic 2000 to prevent postoperative recurrence of crohn's disease. Dig Dis Sci. 2007;52:385–9.

    PubMed  Article  Google Scholar 

  74. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC: Interventions for prevention of post-operative recurrence of crohn's disease. Cochrane Database Syst Rev 2009;CD006873.

  75. Meijer BJ, Dieleman LA: Probiotics in the treatment of human inflammatory bowel diseases: Update 2011. J Clin Gastroenterol. 45 Suppl:S139-144.

  76. Bensoussan M, Jovenin N, Garcia B, et al. Complementary and alternative medicine use by patients with inflammatory bowel disease: Results from a postal survey. Gastroenterol Clin Biol. 2006;30:14–23.

    PubMed  Article  Google Scholar 

  77. Floch MH, Walker WA, Madsen K, et al.: Recommendations for probiotic use-2011 update. J Clin Gastroenterol. 45 Suppl:S168-171.

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

The opinions are solely those of the authors and do not represent an endorsement by the Department of Defense. This is a U.S. Government work. There are no restrictions on its use

Author information

Affiliations

  1. Gastroenterology Service, Department of Medicine, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD, 20889-0001, USA

    Ganesh R. Veerappan, John Betteridge & Patrick E. Young

Authors
  1. Ganesh R. Veerappan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Betteridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick E. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick E. Young.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Veerappan, G.R., Betteridge, J. & Young, P.E. Probiotics for the Treatment of Inflammatory Bowel Disease. Curr Gastroenterol Rep 14, 324–333 (2012). https://doi.org/10.1007/s11894-012-0265-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-012-0265-5

Keywords

  • Inflammatory bowel disease
  • Probiotics
  • Pouchitis
  • Ulcerative colitis
  • Crohn’s disease
  • Efficacy
  • Review
  • VSL#3
  • Sacchromyces boullardi
  • Pathophysiology
  • Flora
  • Commensal
  • Microbiome
  • Therapy
  • Treatment
  • Evidence
  • Trials
  • Bacteria
  • Mechanism of action
  • Bifidobacterium
  • Lactobacillus
  • Alternative therapy
  • Recommendations
  • Dysbiosis
  • Studies